Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the GlaxoSmithKline Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to executive compensation.
| Metric | Value |
|---|---|
| ADS Fair Market Value (Tax Withholding) | $55.80 per ADS |
| ADSs Withheld (Ms D Connelly) | 123 |
| ADSs Withheld (Mr W Louv) | 308 |
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the vesting of post-tax awards on March 4, 2014, and the subsequent withholding of shares to meet tax liabilities.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the vesting date of the 2009 Deferred Annual Bonus Plan awards (March 4, 2014).
- Confirm the fair market value of ADSs used for tax withholding calculations ($55.80).
- Review the specific number of ADSs withheld for Ms D Connelly (123) and Mr W Louv (308).
- Note that this filing does not contain quarterly or annual financial results.